Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKB | Q96GD4 | 9/20 | 0.44 |
| ▸ | SRC | P12931 | 2/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | AURKA | O14965 | 10/20 | 0.42 |
| ▸ | RIPK1 | Q13546 | 6/20 | 0.42 |
| ▸ | AURKC | Q9UQB9 | 4/20 | 0.42 |
| ▸ | PLK4 | O00444 | 3/20 | 0.42 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.42 |
| ▸ | STK25 | O00506 | 1/20 | 0.42 |
| ▸ | RIOK3 | O14730 | 1/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.42 |
| ▸ | GAK | O14976 | 1/20 | 0.42 |
| ▸ | MUSK | O15146 | 1/20 | 0.42 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.42 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.42 |
| ▸ | MAP3K13 | O43283 | 1/20 | 0.42 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.42 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.42 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4908688 | 0.84 | AURKB (0.53) | AURKBSRCGSK3BAURKARIPK1 | |
| SCHEMBL4900184 | 0.75 | NAMPT (0.40) | AURKBSRCGSK3BAURKARIPK1 | |
| SCHEMBL648099 | 0.74 | AURKA (0.58) | AURKBSRCGSK3BAURKARIPK1 | |
| SCHEMBL375438 | 0.74 | AURKB (0.47) | AURKBSRCGSK3BAURKARIPK1 | |
| SCHEMBL13765973 | 0.73 | AURKA (0.54) | AURKBSRCGSK3BAURKARIPK1 | |
| SCHEMBL12338932 | 0.72 | AURKB (0.65) | AURKBSRCAURKARIPK1AURKC | |
| SCHEMBL2204610 | 0.71 | AURKB (0.75) | AURKBSRCGSK3BAURKARIPK1 | |
| SCHEMBL62264 | 0.71 | AURKA (0.55) | AURKBSRCGSK3BAURKARIPK1 | |
| SCHEMBL2203480 | 0.71 | AURKB (0.59) | AURKBSRCGSK3BAURKARIPK1 | |
| SCHEMBL20386846 | 0.71 | AURKA (0.49) | AURKBSRCGSK3BAURKARIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080113946-A1 | N-aryl-5,7-dihydrofuro[3,4-d]pyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYNTOVIA, INC. (US) | 2008-05-15 | — | — | US | claimed |
| US-20080113946-A1 | N-aryl-5,7-dihydrofuro[3,4-d]pyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYNTOVIA, INC. (US) | 2008-05-15 | — | — | US | disclosed |
| US-20080113946-A1 | N-aryl-5,7-dihydrofuro[3,4-d]pyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYNTOVIA, INC. (US) | 2008-05-15 | — | — | US | disclosed |
| US-20080113946-A1 | N-aryl-5,7-dihydrofuro[3,4-d]pyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYNTOVIA, INC. (US) | 2008-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080113946-A1 | N-aryl-5,7-dihydrofuro[3,4-d]pyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof | CASP7, API5, CASP5 | AURKB 267/4885SRC 3361/4885GSK3B 4160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.